A Recent FDA Study Forces Black Box Label on Invokana
Pharmaceutical titans Johnson & Johnson took another massive hit as clinical trials led by the FDA concluded a week ago today, on May 16, 2017. The U.S. Food & Drug Administration wanted to investigate a possible causation between amputations in Type 2 diabetes patients and those taking Invokana to treat it. The clinical studies showed that Type 2 diabetes patients who were prescribed Invokana were twice as likely to suffer an amputation, forcing a black box warning label on the drug.
Invokana is just one brand name of the generic drug, Canagliflozin, which is used to control glucose levels in patients with Type 2 diabetes. Johnson & Johnson manufactures Invokana but also Invokamet and Invokamet XR - similar forms of the drug. As a result of the studies conducted by the FDA, each form of Canagliflozin that Johnson & Johnson produces will be labeled with a black box warning, the severest of warnings the FDA places on harmful drugs made and sold in the United States.
Another Straw on Johnson & Johnson’s Back
This finding is actually just one of many investigations concluding that Johnson & Johnson products are anything but entirely safe. They recently lost a 9-figure verdict to compensate a cancer patient whose condition was caused by their talcum powder. Months before that, via their child company, Janssen Pharmaceuticals, Johnson & Jonson began paying out massive verdicts and settlements for their liability in causing gynecomastia in patients prescribed with the anti-psychotic drug Risperdal.
Has Invokana Caused Your Amputation? We Want to Help
If you are a Type 2 diabetes patient, prescribed with Invokana or one of the other Johnson & Johnson brands, and suffered an amputation, our Pennsylvania defective drug attorneys want to help you fight back against this pharmaceutical company and achieve the compensation you deserve. We have been fighting in the courtroom for over 100 years, collectively. We know what it takes.
To learn more about Invokana and the complications it presents in Type 2 diabetes patients, see information here. For specific inquiries related to your case, call our offices today at (888) 498-3023.